SCYNEXIS
Jersey City, New Jersey, United States · Biotechnology, Health Care
SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections.
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Jersey City, New Jersey, United States
- Employees
- 61
- Industries
- Biotechnology, Health Care
- Status
- Public (SCYX)
- Website
- www.scynexis.com
- Company page
Recent activity at SCYNEXIS
- : SEC 8-K (1.01): On September 25, 2026, SCYNEXIS, Inc. entered into a material definitive agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of SCY-247, a second-generation fungerp antifungal candidate. The BARDA Contract stipulates potential non-dilutive funding of up to $214 million, with an initial base period starting in September 2026 that allocates approximately $18.5 million for advancing SCY-247 into a Phase 2 study in patients with invasive candidiasis. Further funding is contingent on BARDA exercising up to six options, potentially extending the contract for an additional ten years, which underscores the strategic partnership's significance in bolstering antifungal treatment efforts.
- : SEC 8-K (5.02): On September 18, 2026, SCYNEXIS, Inc. appointed Steven K. Burke, M.D., to its Board of Directors. His appointment is effective immediately and will last until the 2027 Annual Meeting of Stockholders. Dr. Burke has also been assigned to the Nominating and Corporate Governance Committee. As compensation, he will receive an annual retainer of $45,000 and an additional $5,000 for committee service, alongside an option grant to purchase 5,750 shares of the company's common stock at an exercise price of $4.46. This change in board composition is expected to enhance governance and oversight for the company.
- : SCYNEXIS Appoints Sanjay Subramanian as New Chief Financial Officer
Employee benefit plans
SCYNEXIS files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
About SCYNEXIS: questions and answers
What does SCYNEXIS do?
SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections.
Where is SCYNEXIS headquartered?
SCYNEXIS is headquartered in Jersey City, New Jersey, United States.
How many employees does SCYNEXIS have?
SCYNEXIS has about 61 employees.
What is the latest news on SCYNEXIS?
On Sep 25, 2026, SEC 8-K (1.01): On September 25, 2026, SCYNEXIS, Inc. entered into a material definitive agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of SCY-247, a second-generation fungerp antifungal candidate. The BARDA Contract stipulates potential
Is SCYNEXIS a public company?
Yes. SCYNEXIS is publicly traded under the ticker SCYX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy